Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

ted at all three doses in this study is very encouraging for the prospects of ANA598 when used in combination with other HCV agents. With the successful conclusion of this study in patients and the 14-day study in healthy volunteers, the positive 13-week animal toxicology results and ongoing manufacturing activities, the ANA598 program continues on track to be ready for Phase II in mid-2009."

The Phase Ib study was a randomized, double-blind, placebo-controlled, multiple ascending dose trial conducted to evaluate the safety, tolerability and antiviral activity of orally administered ANA598 in treatment-naive patients with chronic HCV genotype 1 infection. Patients were treated with ANA598 capsules (or matching placebo) at doses of 200 mg, 400 mg or 800 mg bid for three days. 35 patients participated in the study, with 11 receiving 200 mg bid, eight receiving 400 mg bid, eight receiving 800 mg bid and eight receiving placebo (with none of the patients receiving placebo showing an end of treatment response greater than 0.2 log10 reduction in viral load). Viral load at Day 4 (12 hours after the last dose) was compared to baseline HCV RNA levels.

"We're very pleased with the antiviral activity and safety of ANA598 in this study," commented James Freddo, M.D., Senior Vice President, Drug Development and Chief Medical Officer. "We believe the data continue to position ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV, and we look forward to investigating ANA598 in longer-term studies in combination with current standard of care."

ANA598 Program Update

Anadys continues to make progress on all aspects of the ANA598 program, including toxicology, manufacturing and a recently completed 14-day clinical study in healthy volunteers. The Company reiterates its expectation for the program to be ready mid-year for the first Phase II study of ANA598 in combination wi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... YORK , July 25, 2014  Smile Train ... to showcase their Virtual Surgery Simulator among leading ... which will take place in Washington, D.C. ... the Performing Arts. "Smile Train is ... alongside the talented community of innovators in health and ...
(Date:7/25/2014)... -- GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to announce ... LaurelCo, LLC, an Illinois limited liability ... dispensary medical marijuana licenses in the state of ... a 20% equity interest in LaurelCo, LLC in exchange for ... as well as all technology related to the machines and ...
(Date:7/25/2014)... -- Solanbridge Group Inc (OTC: SLNX) is pleased to announce ... and the Letter of Intent issued on July 11, ... Agreement. Charles R. Shirley , Managing ... Mr. David Pecoraro and Buzznbrewz.com join SLNX,s ... sector and developed a tremendous network of contacts who ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... LOUIS, Aug. 30, 2011 The Board of Directors of ... its regularly scheduled board meeting that it reaffirmed the Company,s ... platform and expansion of the Odyssey ™  platform into ... Board reviewed and endorsed the commercial strategies put forth for ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, announced today that Arthur T. ... officer, will present at the Stifel Nicolaus Healthcare Conference ... p.m. Eastern Time.  Dr. Sands will provide an overview ...
Cached Medicine Technology:Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 2Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 3Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference 2
(Date:7/28/2014)... July 28, 2014 Mitul R. Patel, ... gathered at the MGE Management Experts Benefit Dinner May ... leaders joined the Dentists to raise funds for the ... and Girls Clubs and Youth Programs across America. The ... people with books and audio books to directly tackle ...
(Date:7/28/2014)... 2014 Dr. Alan Xenakis, MD announced today ... Funny Feelings.” The new book, DOC X MD Funny ... unique story telling style with humor and medical accuracy. The ... reader will find answers to those age-old questions that most ... people pee? Why do mosquitoes bite some and not others? ...
(Date:7/27/2014)... Zensah®, the leader in compression technology and sports medicine, has ... . The wrist support features an adjustable velcro strap and ... Epicondylitis, more commonly referred to as tennis elbow and golfers ... the tendons attached to the outside of the elbow. Although ... work the wrist and fingers turn into a tendon that ...
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are now ... younger appearance. The Cherry News company has published its ... women explore the availabilities from U.S. retailers at ... the posted guide on the Cherry News website provide ... to some natural ingredient formulas is the high sticker ...
(Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
Breaking Medicine News(10 mins):Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... play a role in screening for colorectal cancer (CRC), ... rates, the American Gastroenterological Association (AGA) Institute issued minimum ... competence, a minimum of 75 endoscopically confirmed cases should ... fact that CT colonography has not yet been endorsed ...
... than other chronic conditions , , FRIDAY, Sept. 7 (HealthDay ... may well be the most disabling disease in the ... chronic physical diseases such as angina, arthritis, asthma and ... from depression, the team of international researchers found. , ...
... Home and the ... Workplace-- ... Sept. 7 Quick, convenient, quality,health care has come to the Oklahoma ... the CVS/pharmacy store in Moore at 1040,SW 19th Street. MinuteClinic ( http://www.minuteclinic.com ...
... Group, the,international generic pharmaceuticals company, today announced that ... from the U.S. Food &,Drug Administration. Distribution of ... tablets, the generic equivalent of Pfizer,s,Norvasc(R) tablets, will ... 10 mg strengths,and are indicated for the treatment ...
... BELLEVILLE, ON, Sept. 7 /PRNewswire-FirstCall/ - Bioniche ... Canadian,biopharmaceutical company, today announced that it has ... Economic Development (RED) Program of the,Ontario Ministry ... grant,announced by the Honourable Leona Dombrowsky, Minister ...
... Medicine at The University of Nottingham, has been recognised ... of newborn babies, particularly those born prematurely, with an ... award, by the Good Clinical Practice Journal (GCPj), acknowledges ... in drug development and clinical trials. It is given ...
Cached Medicine News:Health News:Gastroenterology sets standards for CT colonography 2Health News:Gastroenterology sets standards for CT colonography 3Health News:Depression May Be World's Most Disabling Disease 2Health News:Depression May Be World's Most Disabling Disease 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 2Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 4Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 5Health News:Actavis Launches Amlodipine Tablets in the U.S. 2Health News:Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine 2Health News:Academic Researcher of the Year 2007 2
... Alsius heat exchange catheters connect to the ... and maintains a target temperature input by ... patient core temperature and automatically adjusts the ... catheter (0-42C), providing consistent maintenance of temperature. ...
... vascular access. Hollow stylet design ... puncture with two-part needle. Initial ... while maintaining thumb position on ... hub of the stylet. Supplied ...
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used for percutaneous introduction of balloon, electrode and closed or non-tapered end catheters for vascular and non-vascular use....
Medicine Products: